Loading…

Adenosine A2AR in viral immune evasion and therapy: unveiling new avenues for treating COVID-19 and AIDS

Adenosine is a neuro- and immunomodulator that functions via G protein-coupled cell surface receptors. Several microbes, including viruses, use the adenosine signaling pathway to escape from host defense systems. Since the recent research developments in its role in health and disease, adenosine and...

Full description

Saved in:
Bibliographic Details
Published in:Molecular biology reports 2024-12, Vol.51 (1), p.894, Article 894
Main Authors: Atif, Muhammad, Alsrhani, Abdullah, Naz, Farrah, Ullah, Sajjad, Abdalla, Abualgasim Elgaili, Ullah, Muhammad Ikram, Mazhari, Bi Bi Zainab, Eltayeb, Lienda Bashier, Hamad, Ismail, Ejaz, Hasan
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c256t-6305e264a4599863471bd1bfa14a9c7375d72ce1d2256fd10bc11ef425340f363
container_end_page
container_issue 1
container_start_page 894
container_title Molecular biology reports
container_volume 51
creator Atif, Muhammad
Alsrhani, Abdullah
Naz, Farrah
Ullah, Sajjad
Abdalla, Abualgasim Elgaili
Ullah, Muhammad Ikram
Mazhari, Bi Bi Zainab
Eltayeb, Lienda Bashier
Hamad, Ismail
Ejaz, Hasan
description Adenosine is a neuro- and immunomodulator that functions via G protein-coupled cell surface receptors. Several microbes, including viruses, use the adenosine signaling pathway to escape from host defense systems. Since the recent research developments in its role in health and disease, adenosine and its signaling pathway have attracted attention for targeting to treat many diseases. The therapeutic role of adenosine has been extensively studied for neurological, cardiovascular, and inflammatory disorders and bacterial pathophysiology, but published data on the role of adenosine in viral infections are lacking. Therefore, the purpose of this review article was to explain in detail the therapeutic role of adenosine signaling against viral infections, particularly COVID-19 and HIV. Several therapeutic approaches targeting A2AR-mediated pathways are in development and have shown encouraging results in decreasing the intensity of inflammatory reaction. The hypoxia–adenosinergic mechanism provides protection from inflammation-mediated tissue injury during COVID-19. A2AR expression increased remarkably in CD39 + and CD8 + T cells harvested from HIV patients in comparison to healthy subjects. A combined in vitro treatment performed by blocking PD-1 and CD39/adenosine signaling produced a synergistic outcome in restoring the CD8 + T cells funstion in HIV patients. We suggest that A2AR is an ideal target for pharmacological interventions against viral infections because it reduces inflammation, prevents disease progression, and ultimately improves patient survival.
doi_str_mv 10.1007/s11033-024-09839-1
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3090637633</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3090637633</sourcerecordid><originalsourceid>FETCH-LOGICAL-c256t-6305e264a4599863471bd1bfa14a9c7375d72ce1d2256fd10bc11ef425340f363</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi0EokvhD3BAlrj0YvB47DjmFm35WKlSJb6uljdxWleJs9jJov57vLsFJA6cRpp53ndG8xLyEvgb4Fy_zQAckXEhGTc1GgaPyAqURiaNrh-TFUcOTNYKzsiznO845xK0ekrO0AAopWFFbpvOxymH6Gkjms80RLoPyQ00jONSmn7vcpgidbGj861Pbnf_ji5x78MQ4g2N_id1ex8Xn2k_JTon7-bDYH39fXPJwByFzebyy3PypHdD9i8e6jn59uH91_UndnX9cbNurlgrVDWzCrnyopJOKmPqCqWGbQfb3oF0ptWoVadF66ETBe874NsWwPdSKJS8xwrPycXJd5emH-Ws2Y4ht34YXPTTki1ywyvUFWJBX_-D3k1LiuW6I6UV1uJgKE5Um6ack-_tLoXRpXsL3B5ysKccbMnBHnOwUESvHqyX7ei7P5Lfjy8AnoBcRvHGp7-7_2P7C78Tj-U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3090753826</pqid></control><display><type>article</type><title>Adenosine A2AR in viral immune evasion and therapy: unveiling new avenues for treating COVID-19 and AIDS</title><source>Springer Nature</source><creator>Atif, Muhammad ; Alsrhani, Abdullah ; Naz, Farrah ; Ullah, Sajjad ; Abdalla, Abualgasim Elgaili ; Ullah, Muhammad Ikram ; Mazhari, Bi Bi Zainab ; Eltayeb, Lienda Bashier ; Hamad, Ismail ; Ejaz, Hasan</creator><creatorcontrib>Atif, Muhammad ; Alsrhani, Abdullah ; Naz, Farrah ; Ullah, Sajjad ; Abdalla, Abualgasim Elgaili ; Ullah, Muhammad Ikram ; Mazhari, Bi Bi Zainab ; Eltayeb, Lienda Bashier ; Hamad, Ismail ; Ejaz, Hasan</creatorcontrib><description>Adenosine is a neuro- and immunomodulator that functions via G protein-coupled cell surface receptors. Several microbes, including viruses, use the adenosine signaling pathway to escape from host defense systems. Since the recent research developments in its role in health and disease, adenosine and its signaling pathway have attracted attention for targeting to treat many diseases. The therapeutic role of adenosine has been extensively studied for neurological, cardiovascular, and inflammatory disorders and bacterial pathophysiology, but published data on the role of adenosine in viral infections are lacking. Therefore, the purpose of this review article was to explain in detail the therapeutic role of adenosine signaling against viral infections, particularly COVID-19 and HIV. Several therapeutic approaches targeting A2AR-mediated pathways are in development and have shown encouraging results in decreasing the intensity of inflammatory reaction. The hypoxia–adenosinergic mechanism provides protection from inflammation-mediated tissue injury during COVID-19. A2AR expression increased remarkably in CD39 + and CD8 + T cells harvested from HIV patients in comparison to healthy subjects. A combined in vitro treatment performed by blocking PD-1 and CD39/adenosine signaling produced a synergistic outcome in restoring the CD8 + T cells funstion in HIV patients. We suggest that A2AR is an ideal target for pharmacological interventions against viral infections because it reduces inflammation, prevents disease progression, and ultimately improves patient survival.</description><identifier>ISSN: 0301-4851</identifier><identifier>ISSN: 1573-4978</identifier><identifier>EISSN: 1573-4978</identifier><identifier>DOI: 10.1007/s11033-024-09839-1</identifier><identifier>PMID: 39115571</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Acquired Immunodeficiency Syndrome - drug therapy ; Acquired Immunodeficiency Syndrome - immunology ; Adenosine ; Adenosine - metabolism ; Adenosine receptors ; Animal Anatomy ; Animal Biochemistry ; Apyrase - immunology ; Apyrase - metabolism ; Biomedical and Life Sciences ; CD8 antigen ; CD8-Positive T-Lymphocytes - immunology ; CD8-Positive T-Lymphocytes - metabolism ; Cell surface ; Cell surface receptors ; COVID-19 ; COVID-19 - immunology ; COVID-19 - virology ; COVID-19 Drug Treatment ; G protein-coupled receptors ; Histology ; HIV ; Human immunodeficiency virus ; Humans ; Hypoxia ; Immune Evasion ; Immunomodulation ; Infections ; Inflammatory diseases ; Life Sciences ; Lymphocytes T ; Morphology ; Neurological diseases ; Pathophysiology ; PD-1 protein ; Receptor, Adenosine A2A - metabolism ; Review ; SARS-CoV-2 - immunology ; SARS-CoV-2 - pathogenicity ; SARS-CoV-2 - physiology ; Signal Transduction ; Viral infections</subject><ispartof>Molecular biology reports, 2024-12, Vol.51 (1), p.894, Article 894</ispartof><rights>The Author(s), under exclusive licence to Springer Nature B.V. 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to Springer Nature B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c256t-6305e264a4599863471bd1bfa14a9c7375d72ce1d2256fd10bc11ef425340f363</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39115571$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Atif, Muhammad</creatorcontrib><creatorcontrib>Alsrhani, Abdullah</creatorcontrib><creatorcontrib>Naz, Farrah</creatorcontrib><creatorcontrib>Ullah, Sajjad</creatorcontrib><creatorcontrib>Abdalla, Abualgasim Elgaili</creatorcontrib><creatorcontrib>Ullah, Muhammad Ikram</creatorcontrib><creatorcontrib>Mazhari, Bi Bi Zainab</creatorcontrib><creatorcontrib>Eltayeb, Lienda Bashier</creatorcontrib><creatorcontrib>Hamad, Ismail</creatorcontrib><creatorcontrib>Ejaz, Hasan</creatorcontrib><title>Adenosine A2AR in viral immune evasion and therapy: unveiling new avenues for treating COVID-19 and AIDS</title><title>Molecular biology reports</title><addtitle>Mol Biol Rep</addtitle><addtitle>Mol Biol Rep</addtitle><description>Adenosine is a neuro- and immunomodulator that functions via G protein-coupled cell surface receptors. Several microbes, including viruses, use the adenosine signaling pathway to escape from host defense systems. Since the recent research developments in its role in health and disease, adenosine and its signaling pathway have attracted attention for targeting to treat many diseases. The therapeutic role of adenosine has been extensively studied for neurological, cardiovascular, and inflammatory disorders and bacterial pathophysiology, but published data on the role of adenosine in viral infections are lacking. Therefore, the purpose of this review article was to explain in detail the therapeutic role of adenosine signaling against viral infections, particularly COVID-19 and HIV. Several therapeutic approaches targeting A2AR-mediated pathways are in development and have shown encouraging results in decreasing the intensity of inflammatory reaction. The hypoxia–adenosinergic mechanism provides protection from inflammation-mediated tissue injury during COVID-19. A2AR expression increased remarkably in CD39 + and CD8 + T cells harvested from HIV patients in comparison to healthy subjects. A combined in vitro treatment performed by blocking PD-1 and CD39/adenosine signaling produced a synergistic outcome in restoring the CD8 + T cells funstion in HIV patients. We suggest that A2AR is an ideal target for pharmacological interventions against viral infections because it reduces inflammation, prevents disease progression, and ultimately improves patient survival.</description><subject>Acquired Immunodeficiency Syndrome - drug therapy</subject><subject>Acquired Immunodeficiency Syndrome - immunology</subject><subject>Adenosine</subject><subject>Adenosine - metabolism</subject><subject>Adenosine receptors</subject><subject>Animal Anatomy</subject><subject>Animal Biochemistry</subject><subject>Apyrase - immunology</subject><subject>Apyrase - metabolism</subject><subject>Biomedical and Life Sciences</subject><subject>CD8 antigen</subject><subject>CD8-Positive T-Lymphocytes - immunology</subject><subject>CD8-Positive T-Lymphocytes - metabolism</subject><subject>Cell surface</subject><subject>Cell surface receptors</subject><subject>COVID-19</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 - virology</subject><subject>COVID-19 Drug Treatment</subject><subject>G protein-coupled receptors</subject><subject>Histology</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Hypoxia</subject><subject>Immune Evasion</subject><subject>Immunomodulation</subject><subject>Infections</subject><subject>Inflammatory diseases</subject><subject>Life Sciences</subject><subject>Lymphocytes T</subject><subject>Morphology</subject><subject>Neurological diseases</subject><subject>Pathophysiology</subject><subject>PD-1 protein</subject><subject>Receptor, Adenosine A2A - metabolism</subject><subject>Review</subject><subject>SARS-CoV-2 - immunology</subject><subject>SARS-CoV-2 - pathogenicity</subject><subject>SARS-CoV-2 - physiology</subject><subject>Signal Transduction</subject><subject>Viral infections</subject><issn>0301-4851</issn><issn>1573-4978</issn><issn>1573-4978</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kU1v1DAQhi0EokvhD3BAlrj0YvB47DjmFm35WKlSJb6uljdxWleJs9jJov57vLsFJA6cRpp53ndG8xLyEvgb4Fy_zQAckXEhGTc1GgaPyAqURiaNrh-TFUcOTNYKzsiznO845xK0ekrO0AAopWFFbpvOxymH6Gkjms80RLoPyQ00jONSmn7vcpgidbGj861Pbnf_ji5x78MQ4g2N_id1ex8Xn2k_JTon7-bDYH39fXPJwByFzebyy3PypHdD9i8e6jn59uH91_UndnX9cbNurlgrVDWzCrnyopJOKmPqCqWGbQfb3oF0ptWoVadF66ETBe874NsWwPdSKJS8xwrPycXJd5emH-Ws2Y4ht34YXPTTki1ywyvUFWJBX_-D3k1LiuW6I6UV1uJgKE5Um6ack-_tLoXRpXsL3B5ysKccbMnBHnOwUESvHqyX7ei7P5Lfjy8AnoBcRvHGp7-7_2P7C78Tj-U</recordid><startdate>20241201</startdate><enddate>20241201</enddate><creator>Atif, Muhammad</creator><creator>Alsrhani, Abdullah</creator><creator>Naz, Farrah</creator><creator>Ullah, Sajjad</creator><creator>Abdalla, Abualgasim Elgaili</creator><creator>Ullah, Muhammad Ikram</creator><creator>Mazhari, Bi Bi Zainab</creator><creator>Eltayeb, Lienda Bashier</creator><creator>Hamad, Ismail</creator><creator>Ejaz, Hasan</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20241201</creationdate><title>Adenosine A2AR in viral immune evasion and therapy: unveiling new avenues for treating COVID-19 and AIDS</title><author>Atif, Muhammad ; Alsrhani, Abdullah ; Naz, Farrah ; Ullah, Sajjad ; Abdalla, Abualgasim Elgaili ; Ullah, Muhammad Ikram ; Mazhari, Bi Bi Zainab ; Eltayeb, Lienda Bashier ; Hamad, Ismail ; Ejaz, Hasan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c256t-6305e264a4599863471bd1bfa14a9c7375d72ce1d2256fd10bc11ef425340f363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acquired Immunodeficiency Syndrome - drug therapy</topic><topic>Acquired Immunodeficiency Syndrome - immunology</topic><topic>Adenosine</topic><topic>Adenosine - metabolism</topic><topic>Adenosine receptors</topic><topic>Animal Anatomy</topic><topic>Animal Biochemistry</topic><topic>Apyrase - immunology</topic><topic>Apyrase - metabolism</topic><topic>Biomedical and Life Sciences</topic><topic>CD8 antigen</topic><topic>CD8-Positive T-Lymphocytes - immunology</topic><topic>CD8-Positive T-Lymphocytes - metabolism</topic><topic>Cell surface</topic><topic>Cell surface receptors</topic><topic>COVID-19</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 - virology</topic><topic>COVID-19 Drug Treatment</topic><topic>G protein-coupled receptors</topic><topic>Histology</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Hypoxia</topic><topic>Immune Evasion</topic><topic>Immunomodulation</topic><topic>Infections</topic><topic>Inflammatory diseases</topic><topic>Life Sciences</topic><topic>Lymphocytes T</topic><topic>Morphology</topic><topic>Neurological diseases</topic><topic>Pathophysiology</topic><topic>PD-1 protein</topic><topic>Receptor, Adenosine A2A - metabolism</topic><topic>Review</topic><topic>SARS-CoV-2 - immunology</topic><topic>SARS-CoV-2 - pathogenicity</topic><topic>SARS-CoV-2 - physiology</topic><topic>Signal Transduction</topic><topic>Viral infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Atif, Muhammad</creatorcontrib><creatorcontrib>Alsrhani, Abdullah</creatorcontrib><creatorcontrib>Naz, Farrah</creatorcontrib><creatorcontrib>Ullah, Sajjad</creatorcontrib><creatorcontrib>Abdalla, Abualgasim Elgaili</creatorcontrib><creatorcontrib>Ullah, Muhammad Ikram</creatorcontrib><creatorcontrib>Mazhari, Bi Bi Zainab</creatorcontrib><creatorcontrib>Eltayeb, Lienda Bashier</creatorcontrib><creatorcontrib>Hamad, Ismail</creatorcontrib><creatorcontrib>Ejaz, Hasan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular biology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Atif, Muhammad</au><au>Alsrhani, Abdullah</au><au>Naz, Farrah</au><au>Ullah, Sajjad</au><au>Abdalla, Abualgasim Elgaili</au><au>Ullah, Muhammad Ikram</au><au>Mazhari, Bi Bi Zainab</au><au>Eltayeb, Lienda Bashier</au><au>Hamad, Ismail</au><au>Ejaz, Hasan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adenosine A2AR in viral immune evasion and therapy: unveiling new avenues for treating COVID-19 and AIDS</atitle><jtitle>Molecular biology reports</jtitle><stitle>Mol Biol Rep</stitle><addtitle>Mol Biol Rep</addtitle><date>2024-12-01</date><risdate>2024</risdate><volume>51</volume><issue>1</issue><spage>894</spage><pages>894-</pages><artnum>894</artnum><issn>0301-4851</issn><issn>1573-4978</issn><eissn>1573-4978</eissn><abstract>Adenosine is a neuro- and immunomodulator that functions via G protein-coupled cell surface receptors. Several microbes, including viruses, use the adenosine signaling pathway to escape from host defense systems. Since the recent research developments in its role in health and disease, adenosine and its signaling pathway have attracted attention for targeting to treat many diseases. The therapeutic role of adenosine has been extensively studied for neurological, cardiovascular, and inflammatory disorders and bacterial pathophysiology, but published data on the role of adenosine in viral infections are lacking. Therefore, the purpose of this review article was to explain in detail the therapeutic role of adenosine signaling against viral infections, particularly COVID-19 and HIV. Several therapeutic approaches targeting A2AR-mediated pathways are in development and have shown encouraging results in decreasing the intensity of inflammatory reaction. The hypoxia–adenosinergic mechanism provides protection from inflammation-mediated tissue injury during COVID-19. A2AR expression increased remarkably in CD39 + and CD8 + T cells harvested from HIV patients in comparison to healthy subjects. A combined in vitro treatment performed by blocking PD-1 and CD39/adenosine signaling produced a synergistic outcome in restoring the CD8 + T cells funstion in HIV patients. We suggest that A2AR is an ideal target for pharmacological interventions against viral infections because it reduces inflammation, prevents disease progression, and ultimately improves patient survival.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>39115571</pmid><doi>10.1007/s11033-024-09839-1</doi></addata></record>
fulltext fulltext
identifier ISSN: 0301-4851
ispartof Molecular biology reports, 2024-12, Vol.51 (1), p.894, Article 894
issn 0301-4851
1573-4978
1573-4978
language eng
recordid cdi_proquest_miscellaneous_3090637633
source Springer Nature
subjects Acquired Immunodeficiency Syndrome - drug therapy
Acquired Immunodeficiency Syndrome - immunology
Adenosine
Adenosine - metabolism
Adenosine receptors
Animal Anatomy
Animal Biochemistry
Apyrase - immunology
Apyrase - metabolism
Biomedical and Life Sciences
CD8 antigen
CD8-Positive T-Lymphocytes - immunology
CD8-Positive T-Lymphocytes - metabolism
Cell surface
Cell surface receptors
COVID-19
COVID-19 - immunology
COVID-19 - virology
COVID-19 Drug Treatment
G protein-coupled receptors
Histology
HIV
Human immunodeficiency virus
Humans
Hypoxia
Immune Evasion
Immunomodulation
Infections
Inflammatory diseases
Life Sciences
Lymphocytes T
Morphology
Neurological diseases
Pathophysiology
PD-1 protein
Receptor, Adenosine A2A - metabolism
Review
SARS-CoV-2 - immunology
SARS-CoV-2 - pathogenicity
SARS-CoV-2 - physiology
Signal Transduction
Viral infections
title Adenosine A2AR in viral immune evasion and therapy: unveiling new avenues for treating COVID-19 and AIDS
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T00%3A23%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adenosine%20A2AR%20in%20viral%20immune%20evasion%20and%20therapy:%20unveiling%20new%20avenues%20for%20treating%20COVID-19%20and%20AIDS&rft.jtitle=Molecular%20biology%20reports&rft.au=Atif,%20Muhammad&rft.date=2024-12-01&rft.volume=51&rft.issue=1&rft.spage=894&rft.pages=894-&rft.artnum=894&rft.issn=0301-4851&rft.eissn=1573-4978&rft_id=info:doi/10.1007/s11033-024-09839-1&rft_dat=%3Cproquest_cross%3E3090637633%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c256t-6305e264a4599863471bd1bfa14a9c7375d72ce1d2256fd10bc11ef425340f363%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3090753826&rft_id=info:pmid/39115571&rfr_iscdi=true